Your browser doesn't support javascript.
loading
Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.
Soh, Cheng Hwee; de Sá, Alex G C; Potter, Elizabeth; Halabi, Amera; Ascher, David B; Marwick, Thomas H.
Afiliação
  • Soh CH; Imaging Research Laboratory, Baker Heart and Diabetes Institute, PO Box 6492, Melbourne, VIC, 3004, Australia.
  • de Sá AGC; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.
  • Potter E; Baker Department of Cardiometabolic Health, University of Melbourne, Melbourne, Australia.
  • Halabi A; Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Australia.
  • Ascher DB; School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia.
  • Marwick TH; Systems and Computational Biology, Bio21 Institute, Parkville, Australia.
Cardiovasc Diabetol ; 23(1): 91, 2024 03 06.
Article em En | MEDLINE | ID: mdl-38448993
ABSTRACT

BACKGROUND:

Recent guidelines propose N-terminal pro-B-type natriuretic peptide (NT-proBNP) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes mellitus (T2DM). Wavelet Transform based signal-processing transforms electrocardiogram (ECG) waveforms into an energy distribution waveform (ew)ECG, providing frequency and energy features that machine learning can use as additional inputs to improve the identification of SBHF. Accordingly, we sought whether machine learning model based on ewECG features was superior to NT-proBNP, as well as a conventional screening tool-the Atherosclerosis Risk in Communities (ARIC) HF risk score, in SBHF screening among patients with T2DM.

METHODS:

Participants in two clinical trials of SBHF (defined as diastolic dysfunction [DD], reduced global longitudinal strain [GLS ≤ 18%] or LV hypertrophy [LVH]) in T2DM underwent 12-lead ECG with additional ewECG feature and echocardiography. Supervised machine learning was adopted to identify the optimal combination of ewECG extracted features for SBHF screening in 178 participants in one trial and tested in 97 participants in the other trial. The accuracy of the ewECG model in SBHF screening was compared with NT-proBNP and ARIC HF.

RESULTS:

SBHF was identified in 128 (72%) participants in the training dataset (median 72 years, 41% female) and 64 (66%) in the validation dataset (median 70 years, 43% female). Fifteen ewECG features showed an area under the curve (AUC) of 0.81 (95% CI 0.787-0.794) in identifying SBHF, significantly better than both NT-proBNP (AUC 0.56, 95% CI 0.44-0.68, p < 0.001) and ARIC HF (AUC 0.67, 95%CI 0.56-0.79, p = 0.002). ewECG features were also led to robust models screening for DD (AUC 0.74, 95% CI 0.73-0.74), reduced GLS (AUC 0.76, 95% CI 0.73-0.74) and LVH (AUC 0.90, 95% CI 0.88-0.89).

CONCLUSIONS:

Machine learning based modelling using additional ewECG extracted features are superior to NT-proBNP and ARIC HF in SBHF screening among patients with T2DM, providing an alternative HF screening strategy for asymptomatic patients and potentially act as a guidance tool to determine those who required echocardiogram to confirm diagnosis. Trial registration LEAVE-DM, ACTRN 12619001393145 and Vic-ELF, ACTRN 12617000116325.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Aterosclerose Limite: Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Aterosclerose Limite: Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article